Stifel Financial
YMAB

Stifel Financial’s Y-mAbs Therapeutics YMAB Stock Holding History

Stifel Financial’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-100,000
Closed -$2.61M – 3085
2019
Q3 		$2.61M Hold
100,000
– – 0.01% 1150
2019
Q2 		$2.29M Buy
+100,000
New +$2.3M 0.01% 1252

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Stifel Financial's YMAB Position: Q4 2019 in Review

Stifel Financial sold out of Y-mAbs Therapeutics (YMAB) in Q4 2019, closing a stake of 100,000 shares — an estimated $2.61M sold.

Stifel Financial first reported a position in YMAB in Q2 2019 and held it in 2 quarters. The position peaked at $2.61M in Q3 2019. 81 funds tracked by Wall St. Rank hold YMAB as of Q4 2019.

  • Stifel Financial reported no remaining Y-mAbs Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Stifel Financial sold 100,000 Y-mAbs Therapeutics shares in Q4 2019, an estimated $2.61M.
  • Stifel Financial first reported a position in Y-mAbs Therapeutics in Q2 2019 and held it in 2 quarters.
  • Stifel Financial's Y-mAbs Therapeutics position peaked at $2.61M in Q3 2019.
  • 81 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2019.

Based on Stifel Financial's 13F filing for Q4 2019, filed 13 Feb 2020.